Table 2. Genetic association models of CYP2B6*9 (G516T) variant and the risk of B-CLL.
| CYP2B6*9 (G516T) | B-CLL n (%) | Control n (%) | p-value | OR (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | |||||
| Genotypes | GG | 41.0 | 41% | 79.0 | 79% | Reference | ||
| GT | 39.0 | 39% | 18.0 | 18% | <0.001* | 4.2 | 1.9– 9.3 | |
| TT | 20.0 | 20% | 3.0 | 3% | <0.001* | 12.8 | 3.5–45.6 | |
| Dominant model | GG | 41.0 | 41% | 79.0 | 79% | Reference | ||
| GT + TT | 59.0 | 59% | 21.0 | 21% | <0.001* | 5.4 | 2.8–10 | |
| Recessive model | GG + GT | 80.0 | 80% | 97.0 | 97% | Reference | ||
| TT | 20.0 | 20% | 3.0 | 3% | <0.001* | 8.1 | 2.2–28.3 | |
| Allelic model | G | 128.0 | 64% | 188.0 | 94% | Reference | ||
| T | 72.0 | 36% | 12.0 | 6% | <0.001* | 4.8 | 2.8–7.9 | |
Note: Chi-square test was applied. OR: Odds ratio, CI: Confidence Interval, *: Statistically significant (if p < 0.05).